TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mean sitting systolic blood pressure ≥ 140 mmHg and \< 180 mmHg~* 24-hr mean ambulatory systolic blood pressure ≥ 135 mmHg~Exclusion Criteria:~* Severe hypertension defined as mean sitting systolic blood pressure ≥ 180 mmHg and/or mean sitting diastolic blood pressure ≥ 110 mmHg~* Patients with Type 1 diabetes mellitus~* Secondary hypertension of any etiology~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aliskiren 300 mg (Type: EXPERIMENTAL): Aliskiren tablets starting at a dose of 150 mg taken orally daily for 2 weeks followed by a dose of 300 mg taken orally for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Aliskiren: 1 tablet for the first 2 weeks and 2 tablets during the one week withdrawal period.
- Telmisartan 80 mg (Type: ACTIVE_COMPARATOR): Telmisartan capsules starting at a dose of 40 mg taken orally daily for 2 weeks followed by a dose of 80 mg taken orally daily for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Telmisartan: 1 capsule for the first 2 weeks and 2 capsules during the one week withdrawal period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Aged 6 to 17 years and weight of at least 15 kg~* Meet DSM-IV criteria for of AD, established by chart review, clinical judgment and the Autism Diagnostic Interview- Revised (ADI-R) criteria~* Clinical Global Impressions Severity (CGI-S) score of \>4 (moderately ill)~* ABC Irritability subscale score of \>18~* Mental age of at least 18 months~* If female and sexually active, must agree to an acceptable method of birth control during the trial~* Medication free or adequate washout period (2-4 weeks prior to enrollment) of psychoactive drugs (anticonvulsants permitted for seizure management if dosage is stable for 4 weeks)~* Parent/guardian able to read and provide informed consent.~Exclusion Criteria~* Psychiatric disorder that is effectively managed by psychoactive medication (e.g. ADHD, MDD)~* Prior diagnosis or evidence of genetic or other disorder that may interfere with assessments (e.g. Fragile X syndrome, Fetal alcohol syndrome, history of very low birth weight) assessed by personal and family history, dysmorphology, and clinical judgment.~* Prior use of risperidone or aripiprazole for more than 2 weeks~* Seizure during the past 6 months~* History or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments during the trial including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, hematologic or immunologic disease as determined by the clinical judgment of the investigator~* Current suicidal or homicidal risk~* Positive urine pregnancy test at baseline~* Dependent on other substances, with the exception of nicotine or caffeine

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Risperidone (Type: ACTIVE_COMPARATOR): Atypical antipsychotic
- Aripiprazole (Type: ACTIVE_COMPARATOR): Atypical antipsychotic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Negative rapid diagnostic test for influenza at baseline;~* Immunocompromised participant (liver and/or kidney recipient or allogenic hematopoietic stem cell transplant).~Exclusion Criteria:~* Symptoms suggestive of influenza-like illness; but not limited to fever, cough, or nasal congestion;~* Influenza vaccination in 6 weeks prior to randomization;~* Positive rapid diagnostic test for influenza;~* Solid organ transplant within 6 months of randomization;~* Antiviral treatment for influenza in 2 weeks prior to randomization.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oseltamivir (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neuronal and Behavioral Effects of Implicit Priming in Obese Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight/obese adults~* Healthy weight adults~Exclusion Criteria:~* Vegetarian, vegan, or having other wide-ranging food restrictions~* Currently dieting~* MRI exclusion criteria, if in MRI sample (e.g., claustrophobia, metal in the body)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Active Implicit Priming (MRI sample) (Type: EXPERIMENTAL): Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect. In addition to measures of food image ratings, this group completed a visual food cues scan during fMRI to assess change in neuronal response to food cues. They also completed a measure of food intake post-intervention.
- Control Implicit Priming (MRI sample) (Type: PLACEBO_COMPARATOR): Participants will complete a control implicit priming intervention, which matches the active intervention, but with neutral stimuli as primes. In addition to measures of food image ratings, this group completed a visual food cues scan during fMRI to assess change in neuronal response to food cues. They also completed a measure of food intake post-intervention.
- Active Implicit Priming (Behavioral-only sample) (Type: EXPERIMENTAL): Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect.
- Control Implicit Priming (Behavioral-only sample) (Type: PLACEBO_COMPARATOR): Participants will complete a control implicit priming intervention, which matches the active intervention, but with neutral stimuli as primes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 18 to 75 years~* Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy~* clinical stage tumor 1-4a (cT1-4a), N-/+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition~* No distant metastasis, no direct invasion of pancreas, spleen or other organs nearby in the preoperative examinations~* Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)~* American Society of Anesthesiology score (ASA) class I, II, or III~* Written informed consent~Exclusion Criteria:~* Women during pregnancy or breast-feeding~* Severe mental disorder~* History of previous upper abdominal surgery (except laparoscopic cholecystectomy)~* History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection~* Enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging~* History of other malignant disease within past five years~* History of previous neoadjuvant chemotherapy or radiotherapy~* History of unstable angina or myocardial infarction within past six months~* History of cerebrovascular accident within past six months~* History of continuous systematic administration of corticosteroids within one month~* Requirement of simultaneous surgery for other disease~* Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer~* FEV1\<50% of predicted values~* Diffuse; widespread; plastica

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Indocyanine Green Tracer (Type: EXPERIMENTAL): Indocyanine Green Tracer will be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
- No Indocyanine Green Tracer (Type: ACTIVE_COMPARATOR): Indocyanine Green Tracer will not be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed Hodgkin's lymphoma meeting the following criteria:~  * Newly diagnosed disease~ * Stage IA OR stage IIA without bulky disease~ * No lymphocyte-predominant histology~* Staging on this study will be determined by the clinical stage; surgical staging is strongly discouraged, except for the rare situation of equivocal imaging studies below the diaphragm~* Patients may not have received any previous chemotherapy or radiation therapy; patients may not have received systemic corticosteroids within 30 days of enrollment on this protocol; steroids used for treatment of contrast agent allergy required for computed tomography (CT) scans are acceptable~* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^3~* Total bilirubin =\< 1.5 x normal~* Alanine (ALT) =\< 2.5 x normal~* Shortening fraction \>= 27% by echocardiogram OR ejection fraction \>= 50% by multi-gated acquisition (MUGA)~* No pathologic prolongation of QTc interval on 12-lead electrocardiography (ECG)~* Female patients of childbearing potential must have a negative pregnancy test~* Lactating females must agree that they will not breastfeed a child while on this study~* Fertile patients must use effective contraception~* Males and females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method~* All patients and/or their parents or legal guardians must sign a written informed consent~* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim (Type: EXPERIMENTAL): Treatment consists of 3 cycles of Doxorubicin hydrochloride IV (25 mg/m2) days 1 \& 2, Vincristine sulfate IV (1.4 mg/m2 \[max 2.8 mg\]) Days 1 \& 8, Prednisone orally (40 mg/m2) Days 1-7, Cyclophosphamide IV (600 mg/m2) Days 1 \& 2, Filgrastim by mouth or IV (5 micrograms/kg/dose) 24 hours after Cyclophosphamide complete. See detailed description for remainder of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have successfully completed the Phase 3 Study T-EE04-084 (NCT00251693) or T-EE04-085 (NCT00251719); and have healed esophageal erosions proven by endoscopy. Complete healing was assessed for change in LA Esophagitis Classification grades A, B, C, or D to healed (defined as anything less than the criterion for Grade A). The subject was counted as healed if endoscopy findings did not meet the Grade A criterion.~Exclusion Criteria:~* Use of prescription or nonprescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists, sucralfate, misoprostol, or prokinetics throughout the study~* Use of antacids (except for study supplied) throughout the study.~* Subjects using drugs with significant anticholinergic effects such as tricyclics who cannot stay on a stable dose throughout the study.~* Need for continuous anticoagulant therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR 60 mg QD (Type: EXPERIMENTAL): None
- Dexlansoprazole MR 90 mg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medication-overuse Headache (MOH): Withdrawal or Use of Preventative Medications Directly?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* fulfill 8.2.7 probably medication-overuse headache according to the International Classification of Headache Disorders, 2th Edition (2004)~Exclusion Criteria:~* No benefit of all available preventative medications~* no benefit of abrupt withdrawal lasting more than 3 weeks of acute medication that has been overused~* cluster headache~* chronic paroxysmal hemicrania~* hemicrania continua, pregnancy~* use of pain killers for other reasons than headache~* other reasons for chronic daily headache than medication-overuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis from the start (Type: ACTIVE_COMPARATOR): Use of preventive drugs from the start without abrupt withdrawal
- Abrupt withdrawal (Type: OTHER): Device: Abrupt withdrawal. Standard out-patients detoxication program including telephone call after 2 weeks and rescue medicine up to 2 days/week
- Controls (Type: OTHER): Active control: No instruction for abrupt withdrawal or prophylactic treatment. The controls finished the study period after 5 months observation, and were then offered the optimal type of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participants of either gender aged ≥ 50 years~* Diagnosis of Non-foveal GA secondary to dry AMD~Exclusion Criteria:~* Evidence of Choroidal Neovascularization (CNV)~* GA secondary to any condition other than AMD~* Any prior treatment for AMD or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals~* Any intraocular surgery or thermal laser within three (3) months of trial entry~* Any prior thermal laser in the macular region, regardless of indication~* Any ocular or periocular infection in the twelve (12) weeks~* Previous therapeutic radiation in the region of the study eye~* Any sign of diabetic retinopathy in either eye

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zimura 1 mg [Part 1] (Type: EXPERIMENTAL): Participants received 1 mg of Zimura in the study eye administered via IVT injection (50 µL) on Day 1 and monthly up to 18 months.
- Zimura 2 mg [Part 1] (Type: EXPERIMENTAL): Participants received 2 mg of Zimura in the study eye administered via IVT injection (100 µL) on Day 1 and monthly up to 18 months.
- Sham [Part 1] (Type: SHAM_COMPARATOR): Participants received a Sham injection of an empty, needleless syringe administered in the study eye on Day 1 and monthly up to 18 months.
- Zimura 2 mg (Zimura 2mg+Sham) [Part 2] (Type: EXPERIMENTAL): Participants received 2 mg of Zimura in the study eye administered via IVT injection (100 µL) and a subsequent Sham administration on Day 1 and monthly up to 18 months.
- Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2] (Type: EXPERIMENTAL): Participants received 4 mg of Zimura in the study eye administered via two consecutive IVT injections (2 x 100 µL) on Day 1 and monthly up to 18 months.
- Sham (Sham+Sham) [Part 2] (Type: SHAM_COMPARATOR): Participants received two consecutive Sham injections of empty, needleless syringes administered in the study eye on Day 1 and monthly up to 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy participants~* Participants with Fitzpatrick skin type II or III~* Participant willing to receive Juvéderm® VOLITE in the forearms and agrees to complete all study required procedures, including having 6 cutaneous punch biopsies taken in the forearms and blood drawn (Human immunodeficiency virus \[HIV\], B and C hepatitis analysis at screening)~* Written informed consent and data privacy consent obtained~Exclusion Criteria:~* Pregnant or nursing woman or planning a pregnancy during the study~* Participant participating to another research on human beings or being in an exclusion period for a previous study~* Intensive exposure to sunlight or ultraviolet (UV)-rays within the previous month and foreseen during the study~* Participant having other resorbable filling product injections, a laser treatment, an ultrasound-based treatment, radiation treatment, a dermabrasion, a surgery, a deep chemical peeling or other ablative procedure on the studied zones within the past 12 months prior to study start~* Participant with subcutaneous retaining structure on the studied zones (meshing, threads, gold strand)~* Participant having received injections of permanent or semi-permanent filling products in the studied zones~* Participant under anti-coagulant treatment or treatment liable to interfere with the healing process or hemostasis, during the previous month and during the study~* Participant receiving or is planning to receive anti-inflammatory drugs (oral/injectable corticosteroids or Nonsteroidal anti-inflammatory drugs (NSAIDs), e.g., aspirin, ibuprofen), or other substances known to increase coagulation time (herbal supplements with garlic or ginkgo biloba, etc) for 10 days prior to study treatment and 3 days after~* Participant under immunosuppressive therapy

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Juvéderm® VOLITE (Type: EXPERIMENTAL): Participants received Juvéderm® VOLITE, intradermal injection on a zone of 8 centimeter (cm) x 4 cm (32 cm\^2) of the volar left forearm on Day 0. The dose to be injected was decided by the investigator as per the Directions for Use. A maximum of 1 milliliter (mL) was injected on the zone treated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete